b'Gel and CapillaryResearch Use Only (RUO) AssayB-Cell AssaysT-Cell AssaysTranslocation Assays98/ IGH + IGK B-Cell 108/ TCRB Gene 116/ BCL1/J HTranslocationClonality Assays Clonality AssaysAssay100/ IGH Gene Rearrangement110/ T-Cell Receptor Gama118/ BCL2/J Ht(14;18) AssaysGene Rearrangement Assays 2.0 Translocation Assay 102/ IGH Gene Clonality112/ T-Cell Receptor Gama120/ BCL2/J HTranslocationAssays Gene Rearrangement Assays Assay104/ IGK Gene Clonality 114/ TCRD Gene 122/ BCR/ABL t(9;22) TranslocationAssays Clonality Assays Assays 106/ IGL Gene Clonality 124/ PML/RAR t(15;17) Assays Translocation AssaysMutation Assays126/ IGH Somatic HypermutationAssays v2.0 128/ FLT3 MutationAssaysWARRANTY AND LIABILITYInvivoscribe, Inc. (Invivoscribe) is committed to providing the highest quality products. Invivoscribe warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe. Invivoscribe liability shall not exceed the purchase price of the product. Invivoscribe shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchasers laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of positive, negative, and blank controls every time a sample is tested. Ordering, acceptance, and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.NOTICE: Many of these products in the section that follows are covered by one or more of the following: European Patent Number 1549764, European Patent Number 2418287, European Patent Number 2460889, Japanese Patent Number 4708029, United States Patent 8859748, United States Patent 10280462, and related pending and future applications.All of these patents and applications are licensed exclusively to Invivoscribe, Inc.Additional patents licensed to Invivoscribe covering some of these products apply elsewhere.These products require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). No license under these patents to use amplification processes or enzymes is conveyed expressly or by implication to the purchaser by the purchase of these products.'